Summary of Fortrea (FTRE) Q1 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $636.5 million, a decrease of 2.3% year-over-year, primarily due to lower pass-through costs.

Adjusted EBITDA: $47 million, up from $30.3 million in the prior year, driven by cost savings initiatives.

Net Loss: $23.6 million, significantly improved from a net loss of $562.9 million in the prior year, which was impacted by a goodwill impairment charge.

Book-to-Bill Ratio: 1.15x for Q1 and 1.05x on a trailing 12-month basis.

Backlog: $7.8 billion, with cancellations within historical ranges.

Operating Cash Flow: Negative $17 million, improved from negative $124.2 million in the prior year.

Free Cash Flow: Negative $25 million, compared to negative $127.1 million in the first quarter of 2025.

Top 10 Customers: Represented 54.8% of revenue, with the largest customer accounting for 17.2%.

2Strategic Updates and Business Highlights

Commercial Performance: Strong traction in biotech, with a diversified customer base and improved engagement metrics. The company is focusing on its "3 Rs" strategy: reach, relevance, and repeat.

Launch of Fortrea Intelligent Technology (FIT): A technology suite integrating AI solutions to enhance trial speed and quality, receiving positive feedback from clients.

Operational Excellence: Continued improvements in project management and site activation processes, leading to better delivery and efficiency.

China Market: Notable double-digit growth in opportunities, leveraging a strong operational presence with over 1,000 employees.

3Forward Guidance and Outlook

Revenue Guidance: Reiterated for full year 2026 in the range of $2.55 billion to $2.65 billion.

Adjusted EBITDA Guidance: Targeted between $190 million and $220 million.

Second Quarter Expectations: Anticipated modest sequential revenue increase driven by higher service fee revenue and pass-through costs, with a slight increase in adjusted EBITDA.

4Bad News, Challenges, or Points of Concern

Revenue Decline: The year-over-year revenue decrease was attributed to lower pass-through costs and continued headwinds in Functional Service Provider (FSP) contracts.

Negative Cash Flow: Despite improvements, the company still reported negative operating and free cash flow, highlighting ongoing cash generation challenges.

Market Conditions: While there are signs of recovery in biotech, the overall market remains competitive, with uncertainties around pricing pressures and client renewals.

5Notable Q&A Insights

Biotech Recovery: CEO Anshul Thakral noted a constructive recovery in biotech, with increased RFPs and engagement, indicating potential for sustained growth.

AI Implementation: Discussions around AI focus on collaboration with sponsors to enhance clinical trial efficiency, with no immediate pressure on pricing models.

Margin Improvement: CFO Jill McConnell emphasized that margin improvements will be gradual, with investments aimed at enhancing revenue growth and operational efficiency.

Client Renewals: Thakral indicated a return to normal levels of client renewals, with ongoing efforts to regain stability in the market. Overall, Fortrea's Q1 2026 results reflect a company on a path to recovery, with strategic initiatives aimed at enhancing operational efficiency and commercial performance, despite facing some revenue headwinds and cash flow challenges.